Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

10 Nov 2009 11:21

RNS Number : 2692C
CareCapital Group plc
10 November 2009
 

CareCapital Group plc

TR-1(i)NOTIFICATION OF MAJOR INTERESTS IN SHARES

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

CareCapital Group plc

2. Reason for the notification:

Disposal

3. Full name of person(s) subject to the notification obligation:

Credo Capital plc ("Credo")

4. Full name of shareholder(s):

Credo Group Holdings Limited and its subsidiary, Credo Capital plc

 

5. Date of the transaction (and date on which the threshold is crossed or reached if different):

6 November 2009

6. Date on which issuer notified:

6 November 2009

7. Threshold(s) that is/are crossed or reached:

 9%

8. Notified details:

……………..

A: Voting rights attached to shares

Class/type of shares if possible using the ISIN CODE

Situation previous to the Triggering transaction (vi)

Number of shares

Number of voting Rights (viii)

GB00B16JQ761

6,995,884

6,995,884

Resulting situation after the triggering transaction (vii)

Class/type of shares if possible using the ISIN CODE

Number of shares 

Number of voting rights (ix)

% of voting rights

Direct

Direct (x)

Indirect (xi)

Direct

Indirect

6,859,561

1,666,462

5,193,099

2.17%

6.76%

B: Financial Instruments

Resulting situation after the triggering transaction (xii)

Type of financial instrument

Expiration Date (xiii)

Exercise/Conversion Period/ Date (xiv)

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

Total (A+B)

Number of voting rights

% of voting rights

6,859,561

8.93%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv):

……………..

Proxy Voting:

10. Name of the proxy holder:

……………..

11. Number of voting rights proxy holder will cease to hold:

……………..

12. Date on which proxy holder will cease to hold voting rights:

……………..

13. Additional information:

……………..

14. Contact name:

Ivan Averbuch

15. Contact telephone number:

020 7968 8425

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLBMBBTMMBBBLL
Date   Source Headline
27th Aug 20197:00 amRNSTotal Voting Rights and Directors' Shareholdings
8th Aug 201910:45 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Nearing the end-goal
7th Aug 20197:00 amRNSIssue of equity and new debt facility
6th Aug 201911:05 amRNSSecond Price Monitoring Extn
6th Aug 201911:00 amRNSPrice Monitoring Extension
25th Jul 20195:12 pmRNSResult of AGM
25th Jul 20197:00 amRNSAGM Statement & Technological update
22nd Jul 20197:00 amRNSHarley Street update
28th Jun 20197:00 amRNSFinal Results
3rd Jun 20197:00 amRNSTechnological update
31st May 20195:30 pmRNSTotal Voting Rights
17th May 20195:29 pmRNSHolding(s) in Company
16th May 20192:23 pmEQSAdvanced Oncotherapy (AVO-GB): Strong fundamentals underpin future growth
13th May 201912:20 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Commercialising a breakthrough technology
10th May 20197:00 amRNSDebt facility secured
16th Apr 201910:26 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Preparing for commercialisation
16th Apr 20199:12 amEQSAdvanced Oncotherapy (AVO-GB): Key talent acquisition reaffirms the promise of LIGHT
16th Apr 20197:00 amRNSSenior Management Appointment
7th Mar 20199:00 amRNSPrice Monitoring Extension
22nd Feb 20197:00 amRNSGrant of options
1st Feb 20197:00 amRNSAppointment of Nominated Adviser and Joint Broker
30th Jan 201911:45 amRNSSchedule 2(g) Disclosure
29th Jan 20199:38 amRNSTotal Voting Rights and Significant Shareholdings
24th Jan 201912:14 pmRNSSchedule 2(g) Disclosure
22nd Jan 20193:29 pmRNSResult of General Meeting
21st Jan 201911:15 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Important regulatory milestone: ISO approval
21st Jan 20197:00 amRNSISO 13485:2016 certification for medical devices
21st Dec 201810:15 amRNSLaunch of 2018 SAYE Scheme
21st Dec 20187:00 amRNSProposed Direct Subscription to raise £10.0m
16th Oct 20184:31 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Four components integrated
16th Oct 20183:58 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement
10th Oct 20187:30 amRNSGPSL Research - Flash Note on AVO
10th Oct 20187:00 amRNSTechnological update
4th Oct 201811:07 amRNSGPSL Research - Flash Note on AVO
28th Sep 20187:00 amRNSHalf-year Report
27th Sep 20187:00 amRNSTechnological update
10th Sep 201811:32 amRNSHolding(s) in Company
7th Sep 201811:52 amRNSHolding(s) in Company
3rd Sep 20185:15 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement
3rd Sep 201811:38 amRNSCompletion of the £6.41m Placing
29th Aug 20189:57 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement
28th Aug 20187:00 amRNSDirector Declaration
9th Aug 20187:00 amRNSExercise of Warrants and Issue of Shares
2nd Aug 20187:00 amRNS£6.41m Placing
25th Jul 20183:34 pmRNSResult of AGM
4th Jul 20184:40 pmRNSSecond Price Monitoring Extn
4th Jul 20184:35 pmRNSPrice Monitoring Extension
4th Jul 201811:05 amRNSSecond Price Monitoring Extn
4th Jul 201811:00 amRNSPrice Monitoring Extension
4th Jul 20189:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.